Search Results - "Groves, Morris"

The identification and characterization of breast cancer CTCs competent for brain metastasis by Zhang, Lixin, Ridgway, Lon D, Wetzel, Michael D, Ngo, Jason, Yin, Wei, Kumar, Disha, Goodman, Jerry C, Groves, Morris D, Marchetti, Dario

“…Brain metastatic breast cancer (BMBC) is uniformly fatal and increasing in frequency. Despite its devastating outcome, mechanisms causing BMBC remain largely…”
Get more information

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial by Nassiri, Farshad, Patil, Vikas, Yefet, Leeor S., Singh, Olivia, Liu, Jeff, Dang, Rachel M. A., Yamaguchi, Takafumi N., Daras, Mariza, Cloughesy, Timothy F., Colman, Howard, Kumthekar, Priya U., Chen, Clark C., Aiken, Robert, Groves, Morris D., Ong, Shirley S., Ramakrishna, Rohan, Vogelbaum, Michael A., Khagi, Simon, Kaley, Thomas, Melear, Jason M., Peereboom, David M., Rodriguez, Analiz, Yankelevich, Maxim, Nair, Suresh G., Puduvalli, Vinay K., Aldape, Kenneth, Gao, Andrew, López-Janeiro, Álvaro, de Andrea, Carlos E., Alonso, Marta M., Boutros, Paul, Robbins, Joan, Mason, Warren P., Sonabend, Adam M., Stupp, Roger, Fueyo, Juan, Gomez-Manzano, Candelaria, Lang, Frederick F., Zadeh, Gelareh

“…Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for…”
Get full text

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors by KROP, Ian, DEMUTH, Tim, BLACKMAN, Samuel, WATTERS, James, LOBODA, Andrey, PODTELEZHNIKOV, Alexei, LUNCEFORD, Jared, CONG CHEN, GIANNOTTI, Maxine, HING, Jeremy, BECKMAN, Robert, LORUSSO, Patricia, GUTHRIE, Tina, WEN, Patrick Y, MASON, Warren P, CHINNAIYAN, Prakash, BUTOWSKI, Nicholas, GROVES, Morris D, KESARI, Santosh, FREEDMAN, Steven J

“…Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required…”
Get full text

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study by Lassman, Andrew B, Sepúlveda-Sánchez, Juan Manuel, Cloughesy, Timothy F, Gil-Gil, Miguel J, Puduvalli, Vinay K, Raizer, Jeffrey J, De Vos, Filip Y F, Wen, Patrick Y, Butowski, Nicholas A, Clement, Paul M J, Groves, Morris D, Belda-Iniesta, Cristóbal, Giglio, Pierre, Soifer, Harris S, Rowsey, Steven, Xu, Cindy, Avogadri, Francesca, Wei, Ge, Moran, Susan, Roth, Patrick

“…FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter…”
Get full text

Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment by Chamberlain, Marc C, Glantz, Michael, Groves, Morris D, Wilson, Wyndham H

“…Three methods are routinely used to diagnose neoplastic meningitis (NM): clinical signs and symptoms, cerebrospinal fluid (CSF) cytology, and magnetic…”
Get full text

Phase I study of GRN1005 in recurrent malignant glioma by Drappatz, Jan, Brenner, Andrew, Wong, Eric T, Eichler, April, Schiff, David, Groves, Morris D, Mikkelsen, Tom, Rosenfeld, Steve, Sarantopoulos, John, Meyers, Christina A, Fielding, Robert M, Elian, Kelly, Wang, Xiaolin, Lawrence, Betty, Shing, Mona, Kelsey, Stephen, Castaigne, Jean Paul, Wen, Patrick Y

“…GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein…”
Get full text

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study by Schuster, James, Lai, Rose K, Recht, Lawrence D, Reardon, David A, Paleologos, Nina A, Groves, Morris D, Mrugala, Maciej M, Jensen, Randy, Baehring, Joachim M, Sloan, Andrew, Archer, Gary E, Bigner, Darell D, Cruickshank, Scott, Green, Jennifer A, Keler, Tibor, Davis, Thomas A, Heimberger, Amy B, Sampson, John H

“…The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term…”
Get full text

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics by Kumthekar, Priya U, Avram, Michael J, Lassman, Andrew B, Lin, Nancy U, Lee, Eudocia, Grimm, Sean A, Schwartz, Margaret, Bell Burdett, Kirsten L, Lukas, Rimas V, Dixit, Karan, Perron, Isabella, Zhang, Hui, Gradishar, William J, Pentsova, Elena I, Jeyapalan, Suriya, Groves, Morris D, Melisko, Michelle, Raizer, Jeffrey J

“…Abstract Background Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system…”
Get full text

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer by Malani, Rachna, Fleisher, Martin, Kumthekar, Priya, Lin, Xuling, Omuro, Antonio, Groves, Morris D., Lin, Nancy U., Melisko, Michelle, Lassman, Andrew B., Jeyapalan, Suriya, Seidman, Andrew, Skakodub, Anna, Boire, Adrienne, DeAngelis, Lisa M., Rosenblum, Marc, Raizer, Jeffrey, Pentsova, Elena

“…Purpose The CellSearch® system has been used to identify circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) to diagnose leptomeningeal metastasis (LM)…”
Get full text

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials by Chamberlain, Marc, Soffietti, Riccardo, Raizer, Jeffrey, Rudà, Roberta, Brandsma, Dieta, Boogerd, Willem, Taillibert, Sophie, Groves, Morris D, Le Rhun, Emilie, Junck, Larry, van den Bent, Martin, Wen, Patrick Y, Jaeckle, Kurt A

“…To date, response criteria and optimal methods for assessment of outcome have not been standardized in patients with leptomeningeal metastasis (LM). A Response…”
Get full text

Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma by Maraka, Stefania, Groves, Morris D., Mammoser, Aaron G., Melguizo‐Gavilanes, Isaac, Conrad, Charles A., Tremont‐Lukats, Ivo W., Loghin, Monica E., O’Brien, Barbara J., Puduvalli, Vinay K., Sulman, Erik P., Hess, Kenneth R., Aldape, Kenneth D., Gilbert, Mark R., de Groot, John F., Alfred Yung, W.K., Penas‐Prado, Marta

“…Background Repurposed memantine, mefloquine, and metformin have putative anticancer activity. The objective of this phase 1 study was to determine the maximum…”
Get full text

Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma by Maraka, Stefania, Groves, Morris D., Penas‐Prado, Marta

Get full text

Leptomeningeal Disease by Groves, Morris D., MD, JD

“…Leptomeningeal metastasis (LMD) is a lethal complication caused by a variety of cancers, typically developing late in the disease course. It is associated with…”
Get full text

Prognostic factors and outcomes in patients with leptomeningeal melanomatosis by Harstad, Laura, Hess, Kenneth R, Groves, Morris D

“…The purpose of this study was to describe a cohort of patients with leptomeningeal melanomatosis (LM) and to determine prognostic factors for outcomes in these…”
Get full text

Differentiation of 2‐hydroxyglutarate enantiomers and its lactones by gas chromatography/electron ionization tandem mass spectrometry by Strain, Shinji K., Groves, Morris D., Emmett, Mark R.

“…Rationale 2‐Hydroxyglutarate (2‐hg) exists as enantiomers and can readily undergo cyclization to its lactone. Gas chromatography/electron ionization mass…”
Get full text

Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa by SUKI, Dima, ABOUASSI, Hiba, PATEL, Akash J, SAWAYA, Raymond, WEINBERG, Jeffrey S, GROVES, Morris D

“…The authors tested the hypothesis that patients with metastatic posterior fossa lesions (MPFLs) treated with resection have a higher risk of leptomeningeal…”
Get full text

A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma by Puduvalli, Vinay K, Wu, Jing, Yuan, Ying, Armstrong, Terri S, Vera, Elizabeth, Wu, Jimin, Xu, Jihong, Giglio, Pierre, Colman, Howard, Walbert, Tobias, Raizer, Jeffrey, Groves, Morris D, Tran, David, Iwamoto, Fabio, Avgeropoulos, Nicholas, Paleologos, Nina, Fink, Karen, Peereboom, David, Chamberlain, Marc, Merrell, Ryan, Penas Prado, Marta, Yung, W K Alfred, Gilbert, Mark R

“…Abstract Background Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor…”
Get full text

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma by REARDON, David A, GROVES, Morris D, BO MA, MARTIN CURTIS, C, DAR, Mohammed M, DE BONO, Johann, WEN, Patrick Y, NABORS, Louis, MIKKELSEN, Tom, ROSENFELD, Steve, RAIZER, Jeffrey, BARRIUSO, Jorge, MCLENDON, Roger E, BENJAMIN SUTTLE, A

“…Increased mitogenic signaling and angiogenesis, frequently facilitated by somatic activation of EGF receptor (EGFR; ErbB1) and/or loss of PTEN, and VEGF…”
Get full text

Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis by Suki, Dima, Hatiboglu, Mustafa Aziz, Patel, Akash J, Weinberg, Jeffrey S, Groves, Morris D, Mahajan, Anita, Sawaya, Raymond

“…To test the hypothesis that differential risks of developing leptomeningeal disease (LMD) exist in patients having a single supratentorial brain metastasis…”
Get full text

Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience by Yust-Katz, Shlomit, Mathis, Samuel, Groves, Morris D.

“…Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine…”
Get full text